Filip Janku, MD, PhD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Oncogenic mutations Next generation sequencing PI3K/AKT/mTOR pathway Autophagy Therapeutic targets and molecular aberrations in histiocytic disorders
Click here for the most up-to-date list of Dr. Janku's publications.
Education & Training
Degree-Granting Education
| 2007 | Charles University Prague, Prague, CZE, PHD, Biochemistry |
| 1999 | Charles University Prague, Prague, CZE, MD, Medicine |
Postgraduate Training
| 2009-2011 | Clinical Research Fellowship, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX |
| 2002-2005 | Medical Oncology Fellowship, Department of Oncology, Charles University Prague, Prague |
| 1999-2002 | Residence, Internal Medicine, General Teaching Hospital of Charles University, Prague |
Board Certifications
| 2005 | Medical Oncology - Czech Republic |
| 2002 | Internal Medicine - Czech Republic |
Experience & Service
Academic Appointments
Center Medical Director, Department of Clinical and Translational Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Grant & Contract Support
| Title: | Research Grant to support clinical trials program |
| Funding Source: | Roche |
| Role: | Principal Investigator |
| Title: | Support Clinical Trials Program |
| Funding Source: | Cephalon |
| Role: | Principal Investigator |
| Title: | Phase I study of BRAF inhibitor GSK2118436 and VEGFR/PDGFR/KIT inhibitor pazopanib in patients with advanced refractory malignancies |
| Funding Source: | NCCN |
| Role: | Principal Investigator |
| Title: | A Multi-Center, Open-Label, Phase I Study of Single Agent R7112 Administered Orally in Patients with Advanced Malignancies, Except all Forms of Leukemia |
| Funding Source: | Hoffman-LaRoche, INc |
| Role: | Principal Investigator |
| Title: | A Phase IA, Multicenter, Open-Label Dose Escalation Study Of Oral BYL719, In Adult Patients With Advanced Solid Malignancies, Whose Tumors Have An Alteration Of The PIK3CA Gene |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | A phase Ib open-label, multi-center, dose escalation and expansion study of orally administered MEK162 plus BYL719 in adult patients with selected advanced solid |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | PA13-0344 Next gn sequencing in clinical practice |
| Funding Source: | Foundation One |
| Role: | Principal Investigator |
| Title: | A Phase Ib, Open-Label, Multi-Center, Dose-Escalation Study of Oral BKM120 in Combination with Oral GSK1120212 in Adult Patients with Selected Advanced Solid Tumors |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | Clonal Evolution and Resistance in Gliomas Treated with IDH1 Inhibitors |
| Funding Source: | GBM moon Shot Program |
| Role: | Principal Investigator |
| Title: | Cerebral Spinal Fluid Liquid Biopsies in Brain Tumors |
| Funding Source: | UT Brain |
| Role: | Principal Investigator |
| Title: | A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | Phase I Study of Oral PQR309 in Patients with Advanced Solid Tumor |
| Funding Source: | Piqur |
| Role: | Principal Investigator |
| Title: | A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of DCC-2618 in Patients with Advanced Malignancies |
| Funding Source: | Deciphera |
| Role: | Principal Investigator |
| Title: | A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, includind Glioma, and ith Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 mutation |
| Funding Source: | Agios |
| Role: | Principal Investigator |
| Title: | An Open-Label, Dose-escalation/expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma |
| Funding Source: | Astellas |
| Role: | Principal Investigator |
| Title: | Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-postive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patient with Advanced, Unresectable Solid Tumors |
| Funding Source: | Plexxikon |
| Role: | Principal Investigator |
| Title: | A Phase I Study of AG120 in Patients with Advanced Malignancies with IDH1 Mutations |
| Funding Source: | Agios |
| Role: | Principal Investigator |
| Title: | A Phase I Study of IDH305 in Patients with Advanced Malignancies that harbor IDH1 R132 Mutations |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | Phase I Dose Escalation, Safety, Pharmacokinetic and Pharacodynamic Study of BVD-523 in Patients with Advanced Malignancies |
| Funding Source: | Biomed Valley Discoveries |
| Role: | Principal Investigator |
| Title: | Phase I Safety of Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment - Refractory Solid Tumor Malignancies |
| Funding Source: | Biomed Valley Discoveries |
| Role: | Principal Investigator |
| Title: | Decision Support for Genomic Sequencing in Academic and Community Setting |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | A phase 1, open-label , multi-center, dose-escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands |
| Funding Source: | Novartis |
| Role: | Principal Investigator |